Navitoclax - AbbVie
Alternative Names: ABT-263; RG 7423; RG 7433Latest Information Update: 29 Aug 2024
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie; Genentech
- Class Antifibrotics; Antineoplastics; Benzamides; Morpholines; Piperazines; Senotherapeutics; Small molecules; Sulfones
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myelofibrosis
- Phase I/II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Phase I Haematological malignancies; Ovarian cancer; Triple negative breast cancer
- Discontinued Chronic lymphocytic leukaemia; Crohn's disease; Head and neck cancer; Idiopathic pulmonary fibrosis; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer; Vascular disorders
Most Recent Events
- 29 Aug 2024 Discontinued - Phase-I for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, In adolescents, In children, Second-line therapy or greater, In adults) in Australia (PO)
- 29 Aug 2024 Discontinued - Preclinical for Head and neck cancer (Combination therapy) in USA (PO)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Head-and-neck-cancer(Combination therapy) in USA (PO)